Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients (Q28294491)

11

0 references

author name string

E Ngaimisi

1

0 references

S Mugusi

2

0 references

O M Minzi

3

0 references

P Sasi

4

0 references

K-D Riedel

5

0 references

A Suda

6

0 references

N Ueda

7

0 references

M Janabi

8

0 references

F Mugusi

9

0 references

W E Haefeli

Clinical Pharmacology & Therapeutics

10

0 references

language of work or name

English

0 references

publication date

November 2010

0 references

published in

0 references

volume

88

0 references

issue

5

0 references

page(s)

676-84

0 references

cites work

Higher efavirenz plasma levels correlate with development of insomnia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

Virological rebound after suppression on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Predictors of Virological Success and Ensuing Failure in HIV-Positive Patients Starting Highly Active Antiretroviral Therapy in Europe

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Population pharmacokinetic meta-analysis with efavirenz

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Induction of multiple drug transporters by efavirenz

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Reduced induction of drug metabolism in the elderly

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021

Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.172

7 January 2021